Beyond the Liver: Engineered LNPs Achieve Precision Cardiac Delivery for SCD1 Inhibitor Aramchol

July 26, 2026

PR Newswire Israel

Overview

Galmed, in collaboration with Barcode Nanotech, has developed a groundbreaking lipid nanoparticle (LNP) formulation that precisely redirects its SCD1 inhibitor, Aramchol, from liver hepatocytes to cardiac muscle. This innovative engineering overcomes a significant hurdle in LNP drug delivery, enabling Aramchol’s potential as a disease-modifying therapy for cardiac fibrosis and other chronic heart conditions. The achievement showcases the expanded versatility of LNP technology for highly targeted, organ-specific therapeutic applications.

In Depth

Background

Cardiac fibrosis, characterized by the hardening of heart tissue as a consequence of conditions such as myocardial infarction and hypertension, stands as a leading cause of heart failure. Currently, therapeutic options that directly address and modify cardiac fibrosis are remarkably limited, highlighting a critical unmet medical need. Meanwhile, lipid nanoparticle (LNP) technology has garnered significant acclaim following its pivotal role in RNA vaccines, establishing itself as a versatile and potent platform for drug delivery. However, a persistent challenge for LNP technology has been the strong natural tropism of many formulations for the liver, which has historically complicated efforts to achieve targeted delivery to extrahepatic organs. The recent breakthrough by Galmed and Barcode Nanotech demonstrates a profound leap forward, proving that LNPs can be meticulously engineered for efficient and highly targeted delivery to specific organs beyond the liver, notably the heart, thereby opening new frontiers in advanced delivery technology.

Key Findings

Galmed has announced a significant breakthrough in drug delivery with the successful development of a novel LNP cardiac-targeted formulation for its SCD1 inhibitor, Aramchol. This achievement, a result of a strategic collaboration with Barcode Nanotech, has led to the creation of a unique lipid nanoparticle (LNP) formulation engineered to specifically redirect Aramchol’s biodistribution. Critically, this new formulation shifts the drug’s primary uptake from liver hepatocytes to cardiac muscle, thereby opening unprecedented therapeutic avenues for a range of heart conditions.

Technical Details

Aramchol, Galmed’s SCD1 (Stearoyl-CoA Desaturase 1) inhibitor, has primarily been investigated for its role in treating non-alcoholic fatty liver disease (NAFLD/NASH). However, the innovative application of LNP technology has now expanded its potential target organ to the heart. The novel LNP formulation, developed through a partnership with Barcode Nanotech, incorporates a specific lipid composition and utilizes precise surface modifications. This sophisticated design ensures the LNPs maintain stability within the bloodstream, effectively suppresses non-specific uptake by the liver, and crucially, allows for efficient infiltration and targeted delivery of Aramchol directly to cardiac tissue. Preclinical studies have provided compelling evidence, demonstrating that this LNP Aramchol formulation leads to significantly increased drug concentrations within cardiac cells. Furthermore, these studies have shown promising disease-modifying effects in established models of cardiac fibrosis. SCD1 is an enzyme integral to lipid metabolism, and its inhibition is known to improve myocardial lipid composition, which in turn can potentially suppress inflammation and fibrosis. This cardiac-targeted LNP formulation is therefore expected to offer a transformative therapeutic approach for cardiac fibrosis, a condition with severely limited treatment options once advanced, as well as other chronic cardiac diseases where significant unmet needs persist.

Strategic Significance and Outlook

The development of this LNP cardiac-targeted Aramchol formulation carries the potential to revolutionize the landscape of disease-modifying therapies for cardiac fibrosis and other currently underserved cardiac conditions. If its safety and efficacy are rigorously established through future clinical trials, it could emerge as a groundbreaking treatment option, with the capacity to slow the progression of heart failure and substantially improve patient prognosis and quality of life. Beyond its immediate application, this success is poised to stimulate further advancements in LNP technology, reinforcing its standing as a versatile platform for targeted drug delivery to specific organs. It is anticipated to accelerate research into its application for other organ-specific disease treatments, pushing the realization of personalized medicine through precise drug delivery closer to reality.

Source: https://www.prnewswire.com/news-releases/galmed-announces-the-breakthrough-development-of-novel-lnp-cardiac-targeted-formulation-of-its-scd1-inhibitor-aramchol-302827443.html

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.